

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Health Technology Appraisal

Proposed review of NICE Technology Appraisal guidance no. 96 Hepatitis B (chronic) - adefovir dipivoxil and peginterferon alfa-2a

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Gilead Sciences (Adefovir dipivoxil) • Roche Products Ltd (Peginterferon alfa-2a) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Age Concern England • British Liver Trust • Counsel and Care • Friends of the Elderly • Haemophilia Alliance • Help the Aged • Mainliners • Specialised Healthcare Alliance • The Hepatitis B Foundation UK <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Clinical Microbiologists • Association of Medical Microbiologists • British Association for Services to the Elderly • British Association for Sexual Health and HIV • British Association for the Study of the Liver • British Association for the Study of the Liver Nurses Forum • British Infection Society • British Liver Nurses Forum • British Society of Gastroenterology • Community Practitioners' & Health Visitors Association • Health Protection Agency • Infection Control Nurses Association 	<p><u>General</u></p> <ul style="list-style-type: none"> • Age Concern Cymru • Board of Community Health Councils in Wales • British National Formulary • Department of Health, Social Services and Public Safety for Northern Ireland • Medicines and Healthcare products Regulatory Agency (MHRA) • National Public Health Service for Wales • NHS Confederation • NHS Purchasing and Supply Agency • NHS Quality Improvement Scotland • Scottish Medicines Consortium <p><u>Possible comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> • GlaxoSmithKline (lamivudine) • Roche Products Limited (interferon alfa 2a) • Schering-Plough Ltd (interferon alfa 2a, interferon alfa 2b) • Bristol-Myers Squibb Pharmaceuticals Ltd (entecavir) • Novartis Pharmaceuticals UK Ltd (telbivudine) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Foundation for Liver Research • MRC Clinical Trials Unit <p><u>Assessment team</u></p> <ul style="list-style-type: none"> • National Coordinating Centre for Health Technology Assessment

National Institute for Health and Clinical Excellence
 Review of NICE Technology Appraisal guidance no. 96 Hepatitis B (chronic) - adefovir dipivoxil and peginterferon alfa-2a

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Medical Foundation for AIDS & Sexual Health • National Association of Primary Care • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine – Intellectual Disabilities Forum • Society for General Microbiology • UK Clinical Virology Network • UK Haemophilia Centre Doctors' Organisation • United Kingdom Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Bury PCT • Department of Health • Welsh Assembly Government • Worcestershire PCT 	<p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Collaborating Centre for Women and Children's Health

NICE is committed to promoting equality and eliminating unlawful discrimination.

Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the NHS Research and Development Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.